StockTipsArenaBeta

BUY Dr. Lal Path Labs Ltd. — IDBI Capital

BUYDr. Lal Path Labs Ltd.
Dr. Lal Path Labs share price target & all analyst calls

byIDBI CapitalHorizon: NA (inferred Swing (≤2wk))25 Aug 2026via IDBI Capital Research Calls Telegram

Entry₹1,920Stated
Target₹2,018
Total upside +5.10% (call closed)
Stop loss₹1,871-2.55% risk
Exit₹1,8714 Sept 2026, 9:25 am
Stop-loss hit-2.55%
Follow IDBI Capital for new calls(25% target hit, 375 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 4 Sept 2026
3 supporting0 opposing
Supports the BUY call (3)

Dr. Lal Ventures Private Limited, a wholly-owned subsidiary, has completed the subscription of a 30% stake in Neuome Technologies Private Limited. Neuome now becomes an associate of the company.

BSE · Company Update·27 Aug · 1w ago

(opens in new tab)

3 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·19 Aug · 2w ago

Shri Bajrang Alliance Annual Report: Profit Up, Capacity Expansion Approved

NewsGoogle News·17 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Lal Path Labs

All analyst calls on Dr. Lal Path Labs

More from IDBI Capital

Every call and its outcome